With $32M, Boston Anti-Fungal Startup Morphs Into San Diego’s Cidara

6/30/14Follow @bvbigelow

(Page 2 of 2)

Kevin Forrest of 5AM Ventures, former Achaogen founder and CEO Kevin Judice, and H. Shaw Warren, of Harvard University and Massachusetts General Hospital. Forrest has joined Cidara as chief operating officer and Judice is serving as chief scientific officer. Warren will join Cidara’s scientific advisory board.

Stein joined the company earlier this year as CEO.

In today’s statement, he says, “Our vision is to apply the versatile Cloudbreak small molecule immunotherapy platform to treat patients with compromised immune systems across multiple therapeutic areas. We will initially target patients with compromised immune systems resulting from cancer therapy, bone marrow transplants, and solid organ transplants where the risk of death from invasive fungal infections, even on best available care, often exceeds 50 percent. Our objective is to rewrite the book on how such infections are treated.”

“Current treatment options for patients whose immune systems are severely attenuated by cancer and transplant treatments are typically unsuccessful without reversal of the immune defect,” said Kieren Marr, professor of medicine and oncology and director of the oncology, transplant and infectious diseases program at the Johns Hopkins University School of Medicine and advisor to Cidara. “The Cloudbreak platform’s novel approach of redirecting the immune system may offer major advances in developing treatments for these patients.”

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.